Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not ( P = @ for test of interaction ) , but had no clear detrimental effect on functional outcome at @ months in this group ( P = @ for test of interaction ) .